Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection.

A.J. Baillie, T. F. Dolan, K. C. Carter, J. Alexander

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The effect of initiating drug treatment (free, liposomal or surfactant vesicle forms of stibogluconate) at different times post-infection in Leishmania donovani infected BALB/c mice was studied. It was found that free stibogluconate therapy was less effective at the later stages of infection, i.e. there was a right shifting of the dose response curve. Treatment with either carrier form of the drug was less sensitive to the length of infection so that the benefit obtained by using this form of the drug dramatically increased over the course of infection. The liposomal and surfactant vesicle forms of the drug were equally effective and they were always more suppressive than the free drug. It is proposed that the successful therapeutic outcome of drug treatment is dependent on the interaction of the innate antileishmanial activity of the drug and a host factor(s), which can either augment or reduce the inherent activity of the drug.
LanguageEnglish
Pages23-28
Number of pages6
JournalInternational Journal of Pharmaceutics
Volume57
Issue number1
DOIs
Publication statusPublished - 15 Dec 1989

Fingerprint

Antimony Sodium Gluconate
Visceral Leishmaniasis
Infection
Pharmaceutical Preparations
Surface-Active Agents
Therapeutics
Leishmania donovani
Drug Carriers

Keywords

  • Visceral leishmaniasis
  • mouse
  • sodium stibogluconate
  • infection

Cite this

@article{37ba33599f584097999dfe509f0f8aee,
title = "Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection.",
abstract = "The effect of initiating drug treatment (free, liposomal or surfactant vesicle forms of stibogluconate) at different times post-infection in Leishmania donovani infected BALB/c mice was studied. It was found that free stibogluconate therapy was less effective at the later stages of infection, i.e. there was a right shifting of the dose response curve. Treatment with either carrier form of the drug was less sensitive to the length of infection so that the benefit obtained by using this form of the drug dramatically increased over the course of infection. The liposomal and surfactant vesicle forms of the drug were equally effective and they were always more suppressive than the free drug. It is proposed that the successful therapeutic outcome of drug treatment is dependent on the interaction of the innate antileishmanial activity of the drug and a host factor(s), which can either augment or reduce the inherent activity of the drug.",
keywords = "Visceral leishmaniasis, mouse, sodium stibogluconate, infection",
author = "A.J. Baillie and Dolan, {T. F.} and Carter, {K. C.} and J. Alexander",
year = "1989",
month = "12",
day = "15",
doi = "10.1016/0378-5173(89)90259-7",
language = "English",
volume = "57",
pages = "23--28",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
number = "1",

}

Visceral leishmaniasis in the BALB/c mouse : sodium stibogluconate treatment during acute and chronic stages of infection. / Baillie, A.J.; Dolan, T. F. ; Carter, K. C.; Alexander , J.

In: International Journal of Pharmaceutics, Vol. 57, No. 1, 15.12.1989, p. 23-28.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Visceral leishmaniasis in the BALB/c mouse

T2 - International Journal of Pharmaceutics

AU - Baillie, A.J.

AU - Dolan, T. F.

AU - Carter, K. C.

AU - Alexander , J.

PY - 1989/12/15

Y1 - 1989/12/15

N2 - The effect of initiating drug treatment (free, liposomal or surfactant vesicle forms of stibogluconate) at different times post-infection in Leishmania donovani infected BALB/c mice was studied. It was found that free stibogluconate therapy was less effective at the later stages of infection, i.e. there was a right shifting of the dose response curve. Treatment with either carrier form of the drug was less sensitive to the length of infection so that the benefit obtained by using this form of the drug dramatically increased over the course of infection. The liposomal and surfactant vesicle forms of the drug were equally effective and they were always more suppressive than the free drug. It is proposed that the successful therapeutic outcome of drug treatment is dependent on the interaction of the innate antileishmanial activity of the drug and a host factor(s), which can either augment or reduce the inherent activity of the drug.

AB - The effect of initiating drug treatment (free, liposomal or surfactant vesicle forms of stibogluconate) at different times post-infection in Leishmania donovani infected BALB/c mice was studied. It was found that free stibogluconate therapy was less effective at the later stages of infection, i.e. there was a right shifting of the dose response curve. Treatment with either carrier form of the drug was less sensitive to the length of infection so that the benefit obtained by using this form of the drug dramatically increased over the course of infection. The liposomal and surfactant vesicle forms of the drug were equally effective and they were always more suppressive than the free drug. It is proposed that the successful therapeutic outcome of drug treatment is dependent on the interaction of the innate antileishmanial activity of the drug and a host factor(s), which can either augment or reduce the inherent activity of the drug.

KW - Visceral leishmaniasis

KW - mouse

KW - sodium stibogluconate

KW - infection

U2 - 10.1016/0378-5173(89)90259-7

DO - 10.1016/0378-5173(89)90259-7

M3 - Article

VL - 57

SP - 23

EP - 28

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

ER -